This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
1. Novartis agreed to acquire Tourmaline Bio for $1.4 billion. 2. Tourmaline shareholders will receive $48 per share. 3. Acquisition adds potential therapy for cardiovascular diseases to Novartis. 4. Tourmaline’s drug, pacibekitug, is in advanced Phase 2 trials. 5. Transaction expected to close in Q4 2025.